Does number of dosing sessions and type of adjunctive psychotherapy affect outcomes in psychedelic-assisted-psychotherapy for depressive disorders and anxiety disorders? A systematic review and meta-analysis
Authors:
Open Access
- 20 November 2025
- journal article
- review article
- Published by Elsevier in Journal of Affective Disorders
- Vol. 395 (Pt A) , 120732
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive EpisodesJAMA Psychiatry, 2024
- In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trialsPsychopharmacology, 2024
- Single-Dose Psilocybin Treatment for Major Depressive DisorderJAMA, 2023
- Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II StudyBiological Psychiatry, 2022
- Ancient Roots of Today’s Emerging Renaissance in Psychedelic MedicineCulture, Medicine, and Psychiatry, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive DisorderJAMA Psychiatry, 2021
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-upPsychopharmacology, 2017
- Mind‐altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?EMBO Reports, 2014
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage CancerArchives of General Psychiatry, 2011
- On tests of the overall treatment effect in meta‐analysis with normally distributed responsesStatistics in Medicine, 2001